^
Association details:
| Biomarker: | NRG1 rearrangement |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
In contrast, response was not achieved with anti-ERBB2 therapy (afatinib) in four patients with NRG1-rearranged IMA (including the index patient post-GSK2849330).
Published date:
04/02/2018
Excerpt:
In contrast, response was not achieved with anti-ERBB2 therapy (afatinib) in four patients with NRG1-rearranged IMA (including the index patient post-GSK2849330).
DOI:
10.1158/2159-8290.CD-17-1004
